Comparing the Effectiveness of Education Versus Digital Cognitive Behavioral Therapy for Adults With Sickle Cell Disease: Protocol for the Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications (CaRISMA) Study

Abstract

Background Patients with sickle cell disease (SCD) experience significant medical and psychological stressors that affect their mental health, well-being, and disease outcomes. Digital cognitive behavioral therapy (CBT) has been used in other patient populations and has demonstrated clinical benefits. Although evidence-based, nonpharmacological interventions for pain management are widely used in other populations, these treatments have not been well studied in SCD. Currently, there are no adequately powered large-scale clinical trials to evaluate the effectiveness and dissemination potential of behavioral pain management for adults with SCD. Furthermore, some important details regarding behavioral therapies in SCD remain unclear—in particular, what works best for whom and when. Objective Our primary goal is to compare the effectiveness of two smartphone–delivered programs for reducing SCD pain symptoms: digital CBT versus pain and SCD education (Education). Our secondary goal is to assess whether baseline depression symptoms moderate the effect of interventions on pain outcomes. We hypothesize that digital CBT will confer greater benefits on pain outcomes and depressive symptoms at 6 months and a greater reduction in health care use (eg, opioid prescriptions or refills or acute care visits) over 12 months. Methods The CaRISMA (Cognitive Behavioral Therapy and Real-time Pain Management Intervention for Sickle Cell via Mobile Applications) study is a multisite comparative effectiveness trial funded by the Patient-Centered Outcomes Research Institute. CaRISMA is conducted at six clinical academic sites, in partnership with four community-based organizations. CaRISMA will evaluate the effectiveness of two 12-week health coach–supported digital health programs with a total of 350 participants in two groups: CBT (n=175) and Education (n=175). Participants will complete a series of questionnaires at baseline and at 3, 6, and 12 months. The primary outcome will be the change in pain interference between the study arms. We will also evaluate changes in pain intensity, depressive symptoms, other patient-reported outcomes, and health care use as secondary outcomes. We have 80% power to detect a difference of 0.37 SDs between study arms on 6-month changes in the outcomes with 15% expected attrition at 6 months. An exploratory analysis will examine whether baseline depression symptoms moderate the effect of the intervention on pain interference. Results This study will be conducted from March 2021 through February 2022, with results expected to be available in February 2023. Conclusions Patients with SCD experience significant disease burden, psychosocial stress, and impairment of their quality of life. CaRISMA proposes to leverage digital technology and overcome barriers to the routine use of behavioral treatments for pain and depressive symptoms in the treatment of adults with SCD. The study will provide data on the comparative effectiveness of digital CBT and Education approaches and evaluate the potential for implementing evidence-based behavioral interventions to manage SCD pain. Trial Registration ClinicalTrials.gov NCT04419168; https://clinicaltrials.gov/ct2/show/NCT04419168. International Registered Report Identifier (IRRID) PRR1-10.2196/29014

Barriers to medication adherence in sickle cell disease: A comprehensive theory‐based evaluation using the COM‐B model

“…In an earlier study, our group found that patients with no or few barriers were more likely to have higher HU adherence rates, supporting our findings in this study among AYA with SCD 47 . Moreover, there has been growing and strong evidence to support the effectiveness of digital behavior interventions in improving medication adherence rates, 61–66 and this approach should be explored more among children and AYA with chronic hematological conditions, including SCD 67,68 …”

Effects of Music Therapy on Quality of Life in Adults with Sickle Cell Disease (MUSIQOLS): A Mixed Methods Feasibility Study

“…Currently, cognitivebehavioral therapy (CBT) has strong supporting evidence for managing pain in individuals with SCD, [21][22][23] though several barriers (eg lack of access, cost, and stigma associated with seeking mental health services) remain that prevent individuals with SCD from receiving quality CBT pain services. 24 CBT interventions contain elements that can serve as the foundation for music therapy interventions for SCD pain relief. These elements include pain psycho-education, breathing exercises, imagery, reinterpreting pain sensations, calming self-statements, and relaxation training.…”

A Systematic Review of Adherence to Immunosuppression among Pediatric Heart Transplant Patients

“…In addition to transition programs, there may be a role for technology-based interventions to improve adherence in heart transplant patients. Digital interventions are already being used for children and adolescents with many chronic health conditions [ 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 ]. Gomis-Pastor et al published one of the first studies using a mobile health intervention (mHeart) to improve immunosuppression adherence in adult heart transplant patients [ 48 ].…”